Damora Therapeutics (DMRA) Total Non-Current Liabilities (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Total Non-Current Liabilities came in at $23.8 million in Q1 2026, up 1378.09% YoY from $1.6 million in Q1 2025, and up 18.67% on a QoQ basis from $20.1 million in Q4 2025.
Damora Therapeutics (DMRA) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 5 years of Total Non-Current Liabilities data on file, last reported at $23.8 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 1378.09% year-over-year to $23.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.8 million (up 1378.09% YoY) and the FY2025 annual result came in at $20.1 million, up 1495.07% from the prior year.
- Total Non-Current Liabilities improved to $23.8 million in Q1 2026, from $20.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $23.8 million in Q1 2026 to a low of $1.3 million in Q4 2024.
- A 3-year average of $8.7 million and a median of $2.7 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities jumped 1495.07% — and 2026, when it soared 1378.09%.
- Tracing DMRA's Total Non-Current Liabilities over 3 years: stood at $1.3 million in 2024, then jumped by 1495.07% to $20.1 million in 2025, then increased by 18.67% to $23.8 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $23.8 million (Q1 2026), $20.1 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | 18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.05 Mn |
| Mar 31, 2026 | 23.81 Mn |
| Dec 31, 2025 | 20.07 Mn |
| Sep 30, 2025 | 2.68 Mn |
| Jun 30, 2025 | 2.69 Mn |
| Mar 31, 2025 | 1.61 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2020 | 8.87 Mn |
| Dec 31, 2019 | 8.14 Mn |